Masimo Corp. (MASI) announced Wednesday that Michelle Brennan, currently a board member, will assume the role of interim CEO following the resignation of Chairman and CEO Joe Kiani.
Moreover, Masimo confirmed its non-GAAP financial guidance for the third quarter of 2024, initially released on August 6, 2024.
Presently, the company's shares are experiencing a rise of over 6 percent in pre-market trading.
Brennan, who joined the Board in 2023, brings over three decades of experience as a senior executive at Johnson & Johnson, where she oversaw global medical device and consumer pharmaceutical operations.
To aid in the search for a new CEO, the company has engaged the executive search firm Korn Ferry.
As of now, MASI's stock is trading at $133.84, marking a 6.09% increase on the Nasdaq.
